SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Star Therapeutics, a biotechnology company focused on the discovery and development of life-changing therapies for diseases with significant unmet need, today announced a $200 million private financing. The financing follows the July 2026 acquisition of Star subsidiary Vega Therapeutics and was co-led by OrbiMed and Janus Henderson Investors, with participation from Agent Capital, Catalio Capital Management, Cormorant Asset Management, New Leaf Vent

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.